In the last trading session, 30.59 million shares of the Jaguar Health Inc (NASDAQ:JAGX) were traded, and its beta was 1.00. Most recently the company’s share price was $0.16, and it changed around -$0.02 or -11.41% from the last close, which brings the market valuation of the company to $43.34M. JAGX currently trades at a discount to its 52-week high of $1.22, offering almost -662.5% off that amount. The share price’s 52-week low was $0.05, which indicates that the current value has risen by an impressive 68.75% since then. We note from Jaguar Health Inc’s average daily trading volume that its 3-month average coming to 58.63 million.
Jaguar Health Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended JAGX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Jaguar Health Inc is expected to report earnings per share of $Janux Therapeutics, Inc. for the current quarter.
Jaguar Health Inc (NASDAQ:JAGX) trade information
Instantly JAGX has showed a red trend with a performance of -11.41% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 3.63% year-to-date, but still up 73.75% over the last five days. On the other hand, Jaguar Health Inc (NASDAQ:JAGX) is 96.37% up in the 30-day period.
Jaguar Health Inc (JAGX) estimates and forecasts
Jaguar Health Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -54.10 percent over the past six months and at a 77.65% annual growth rate that is well above the industry average of 10.20%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 86.10%.
JAGX Dividends
Jaguar Health Inc’s next quarterly earnings report is expected to be released in May.
